XANTUS-EL: A Real-World, Prospective, Observational Study of Patients Treated With Rivaroxaban For Stroke Prevention In Atrial Fibrillation In Eastern Europe, Middle East, Africa And Latin America | ||||
| Cardiovascular Research Prove Journal | ||||
| Volume 1, Issue 1, 2017 PDF (252.43 K) | ||||
| Document Type: Abstracts | ||||
| DOI: 10.21608/cvrepj.2017.352431 | ||||
 View on SCiNiTO | ||||
| Abstract | ||||
| The real-world, international, prospective, observational XANTUS study demonstrated low rates of stroke and major bleeding in an unselected atrial fibrillation (AF) patient population treated with rivaroxaban in routine clinical practice in Europe, Canada and Israel. XANTUS-EL is a sister study to XANTUS with the aim to investigate the safety and effectiveness of rivaroxaban in routine clinical use in patients with AF in Eastern Europe, Middle East, Africa and Latin America. | ||||
|
Statistics Article View: 65 PDF Download: 44 |
||||
